Global Diagnostic Biomarker Market Research and Forecast 2018-2023
Diagnosis is defined as an assessment to identify the root cause of an illness and the effects caused by the diseases or illness. It enables to determine the symptoms caused by the illness, and solution to overcome the disease. The diagnostic biomarkers are substances that are used to identify the presence of different disease in an individual. The biomarkers are required so that treatment can be done according to the type of diseases diagnosed. The diagnostic biomarkers are used in many ways such as some of the biomarkers are utilized to assess an individual’s chances of developing diseases, some are utilized for detection of any diseases at initial stages that is for screening and identification that is for diagnosis. Diagnostic biomarkers are used to determine whether a patient has a particular medical condition for which the treatment can be indicated, or an individual should be enrolled in a clinical trial studying the disease.
Rising prevalence of chronic diseases such as cancer and cardiology diseases are significantly rising the demand for research and development of diagnostic biomarker. Further, extensive research institutes focused on diagnostic biomarkers and significant growth in the sector of molecular biology are also considered to be the major factors that are driving the growth of the market. The increasing R&D are expected to fuel the growth of the market. For instance, in Canada, Movember Foundation are innovating new diagnostic biomarkers, treatment targets, and support for men living with prostate cancer. Further, advancements in various laboratory techniques and advances in biomedical technologies such as micro-RNA are expected to fuel the market. However, high capital investments are required and profit ratio is low and limited availability of the resources are expected to hinder the growth of the market. Active funding opportunities for research institutes and increasing demand of personalized medicine are expected to create enormous opportunities for the global diagnostic biomarker market.
The global diagnostic biomarker is segmented on the basis of application, diagnostic technique and end user. On the basis of application, the market is segmented into oncology, cardiology, neurology, nephrology and other. There is huge scope for the market in oncology segment due to increasing prevalence of cancer across the globe. large number of research is going on finding diagnostic biomarker for various types of cancer so that early detection can be done. Further, on the basis of diagnostic technique, the market is segmented into ELISA, colorimetric assay, liquid chromatography-mass spectrometry, particle-enhanced turbidimetric immunoassay and other. ELISA diagnostic technique has considerable share in the market as ELISA test can be used for the diagnosis of Lyme diseases, HIV, pernicious anemia, rotavirus, squamous cell carcinoma, Zika virus, and many more. ELISA is performed in four ways: indirect ELISA, direct ELISA, sandwich ELISA and competitive ELISA. On the basis of end user, the market is segmented into hospitals, diagnostic labs and research centres. Research centres holds the largest market share in the market due to the presence of large number of research institute focused on discovery of innovative biomarkers across the globe.
Furthermore, the global Diagnostic Biomarker market is classified on the basis of geographical regions, including North America, Europe, Asia Pacific & RoW. North America leads the global diagnostic biomarkers market followed by Europe and APAC. The growth of the North American market is attributed to the increasing government support for biomarkers discovery and development and growing usage of biomarkers in drug discovery & development by the pharmaceutical companies within the region. Furthermore, APAC is estimated to witness the highest growth rate owing to the favorable government funding for biomarker research and increasing prevalence of cancer within the regional countries. Rising focus of international players in emerging economies and growing demand for advanced healthcare facilities in developing countries such as China and India are the other key factors that have attributed extensively towards the growth of the diagnostic biomarkers market in APAC market.
Some of the key vendors of the global diagnostic biomarker comprise Abbott Diagnostics Inc., F. Hoffmann-La Roche Ltd., Nanostring Technologies Inc. Inova Diagnostic Inc., Exact Sciences Corporation, and Astute Medical Inc. These companies adopt various strategies such as mergers & acquisitions and partnership to be competitive in the aerospace & defense industry. For instance, in January 2017, Qiagen N.V. completed its acquisition of OmicSoft Corporation that provides access to the OmicSoft’s powerful multi-omics data management infrastructure solution and complements Qiagen’s bioinformatics portfolio.
RESEARCH METHODOLOGY
The market study of global Diagnostic Biomarker market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
Financial reports of companies involved in the market
Authentic Public Databases such as me-pedia.org, Cancer.gov, and National Cancer Institute.
Whitepapers, research-papers, and news blogs
Company websites and their product catalogue
The report is intended for research institutes, hospitals, government and pharmaceuticals companies for overall market analysis and competitive analysis. The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers and initial norms. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.
MARKET SEGMENTATION:
Global Diagnostic Biomarker Market is segmented on the basis of regional outlook and following segments:
Global diagnostic biomarker market research and analysis, by end-users
Global diagnostic biomarker market research and analysis, by application
Global diagnostic biomarker market research and analysis, by diagnostic technique
Global diagnostic biomarker market research and analysis, by region
THE REPORT COVERS:
Comprehensive research methodology of global Diagnostic Biomarker market.
This report also includes detailed and extensive market overview with key analyst insights.
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global Diagnostic Biomarker market.
Insights about market determinants which are stimulating the global Diagnostic Biomarker market.
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.
Rising prevalence of chronic diseases such as cancer and cardiology diseases are significantly rising the demand for research and development of diagnostic biomarker. Further, extensive research institutes focused on diagnostic biomarkers and significant growth in the sector of molecular biology are also considered to be the major factors that are driving the growth of the market. The increasing R&D are expected to fuel the growth of the market. For instance, in Canada, Movember Foundation are innovating new diagnostic biomarkers, treatment targets, and support for men living with prostate cancer. Further, advancements in various laboratory techniques and advances in biomedical technologies such as micro-RNA are expected to fuel the market. However, high capital investments are required and profit ratio is low and limited availability of the resources are expected to hinder the growth of the market. Active funding opportunities for research institutes and increasing demand of personalized medicine are expected to create enormous opportunities for the global diagnostic biomarker market.
The global diagnostic biomarker is segmented on the basis of application, diagnostic technique and end user. On the basis of application, the market is segmented into oncology, cardiology, neurology, nephrology and other. There is huge scope for the market in oncology segment due to increasing prevalence of cancer across the globe. large number of research is going on finding diagnostic biomarker for various types of cancer so that early detection can be done. Further, on the basis of diagnostic technique, the market is segmented into ELISA, colorimetric assay, liquid chromatography-mass spectrometry, particle-enhanced turbidimetric immunoassay and other. ELISA diagnostic technique has considerable share in the market as ELISA test can be used for the diagnosis of Lyme diseases, HIV, pernicious anemia, rotavirus, squamous cell carcinoma, Zika virus, and many more. ELISA is performed in four ways: indirect ELISA, direct ELISA, sandwich ELISA and competitive ELISA. On the basis of end user, the market is segmented into hospitals, diagnostic labs and research centres. Research centres holds the largest market share in the market due to the presence of large number of research institute focused on discovery of innovative biomarkers across the globe.
Furthermore, the global Diagnostic Biomarker market is classified on the basis of geographical regions, including North America, Europe, Asia Pacific & RoW. North America leads the global diagnostic biomarkers market followed by Europe and APAC. The growth of the North American market is attributed to the increasing government support for biomarkers discovery and development and growing usage of biomarkers in drug discovery & development by the pharmaceutical companies within the region. Furthermore, APAC is estimated to witness the highest growth rate owing to the favorable government funding for biomarker research and increasing prevalence of cancer within the regional countries. Rising focus of international players in emerging economies and growing demand for advanced healthcare facilities in developing countries such as China and India are the other key factors that have attributed extensively towards the growth of the diagnostic biomarkers market in APAC market.
Some of the key vendors of the global diagnostic biomarker comprise Abbott Diagnostics Inc., F. Hoffmann-La Roche Ltd., Nanostring Technologies Inc. Inova Diagnostic Inc., Exact Sciences Corporation, and Astute Medical Inc. These companies adopt various strategies such as mergers & acquisitions and partnership to be competitive in the aerospace & defense industry. For instance, in January 2017, Qiagen N.V. completed its acquisition of OmicSoft Corporation that provides access to the OmicSoft’s powerful multi-omics data management infrastructure solution and complements Qiagen’s bioinformatics portfolio.
RESEARCH METHODOLOGY
The market study of global Diagnostic Biomarker market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
Financial reports of companies involved in the market
Authentic Public Databases such as me-pedia.org, Cancer.gov, and National Cancer Institute.
Whitepapers, research-papers, and news blogs
Company websites and their product catalogue
The report is intended for research institutes, hospitals, government and pharmaceuticals companies for overall market analysis and competitive analysis. The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers and initial norms. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.
MARKET SEGMENTATION:
Global Diagnostic Biomarker Market is segmented on the basis of regional outlook and following segments:
Global diagnostic biomarker market research and analysis, by end-users
Global diagnostic biomarker market research and analysis, by application
Global diagnostic biomarker market research and analysis, by diagnostic technique
Global diagnostic biomarker market research and analysis, by region
THE REPORT COVERS:
Comprehensive research methodology of global Diagnostic Biomarker market.
This report also includes detailed and extensive market overview with key analyst insights.
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
Analysis of regional regulations and other government policies impacting the global Diagnostic Biomarker market.
Insights about market determinants which are stimulating the global Diagnostic Biomarker market.
Detailed and extensive market segments with regional distribution of forecasted revenues.
Extensive profiles and recent developments of market players.
CHAPTER 1. REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
CHAPTER 2. MARKET OVERVIEW AND INSIGHTS
2.1. MARKET DEFINITION
2.2. PARENT MARKET ANALYSIS: GLOBAL BIOMARKER MARKET
2.3. ANALYST INSIGHT & CURRENT MARKET TRENDS
2.3.1. KEY FINDINGS
2.3.2. RECOMMENDATION
2.3.3. CONCLUSION
2.4. RULES & REGULATIONS
2.4.1.1. UNITED STATES
2.4.1.2. EUROPEAN UNION
2.4.1.3. CHINA
2.4.1.4. JAPAN
2.4.1.5. INDIA
CHAPTER 3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. RISING PREVALENCE OF CHRONIC DISEASES
3.1.2. HIGH NUMBER OF RESEARCH INSTITUTES FOCUSED ON DIAGNOSTIC BIOMARKERS
3.1.3. SIGNIFICANT GROWTH IN THE SECTOR OF MOLECULAR BIOLOGY
3.1.4. ADVANCEMENTS IN VARIOUS LABORATORY TECHNIQUES
3.1.5. ADVANCES IN BIOMEDICAL TECHNOLOGIES SUCH AS MICRO-RNA (MIRNA)
3.2. RESTRAINTS
3.2.1. LACK OF REGULATORY & REIMBURSEMENT SYSTEMS
3.2.2. HIGH CAPITAL INVESTMENTS IS REQUIRED AND PROFIT RATIO IS LOW
3.2.3. LIMITED AVAILABILITY OF THE RESOURCES AND LIMITED STUDIES RELATED TO THE DIAGNOSTIC BIOMARKERS
3.3. OPPORTUNITIES
3.3.1. INCREASING DEMAND OF PERSONALIZED MEDICINE
3.3.2. ACTIVE FUNDING OPPORTUNITIES FOR RESEARCH INSTITUTES
CHAPTER 4. MARKET SEGMENTATION
4.1. GLOBAL DIAGNOSTIC BIOMARKER MARKET, BY APPLICATION
4.1.1. ONCOLOGY
4.1.2. CARDIOLOGY
4.1.3. NEUROLOGY
4.1.4. NEPHROLOGY
4.1.5. OTHER (CYSTIC FIBROSIS, ASPERGILLOSIS, AND TYPE 2 DIABETES MELLITUS (DM))
4.2. GLOBAL DIAGNOSTIC BIOMARKER MARKET, BY DIAGNOSTIC TECHNIQUE
4.2.1. ELISA
4.2.2. COLORIMETRIC ASSAY
4.2.3. LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY
4.2.4. PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY
4.2.5. OTHER
4.3. GLOBAL DIAGNOSTIC BIOMARKER BY END USERS
4.3.1. HOSPITALS & DIAGNOSTIC LABS
4.3.2. RESEARCH CENTRES
CHAPTER 5. COMPETITIVE LANDSCAPE
5.1. KEY COMPANY ANALYSIS
5.2. KEY STRATEGY ANALYSIS
CHAPTER 6. REGIONAL ANALYSIS
6.1. NORTH AMERICAN
6.1.1. UNITED STATES
6.1.2. CANADA
6.2. EUROPE
6.2.1. U.K
6.2.2. GERMANY
6.2.3. ITALY
6.2.4. SPAIN
6.2.5. FRANCE
6.2.6. ROE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.3.4. ROAPAC
6.4. REST OF THE WORLD
CHAPTER 7. COMPANY PROFILES
7.1. ABASTAR MDX INC.
7.2. ABBOTT LABORATORIES INC.
7.3. ACUMEN PHARMACEUTICALS INC.
7.4. ADLYFE INC.
7.5. AGENDIA BV
7.6. ASTELLAS PHARMA INC.
7.7. ASTUTE MEDICAL, INC.
7.8. AVACTA GROUP PLC
7.9. BANYAN BIOMARKERS
7.10. BAYER AG
7.11. BECKMAN COULTER INC.
7.12. BECTON, DICKSON & CO.
7.13. BG MEDICINE INC.
7.14. BIOMARKER TECHNOLOGIES, INC.
7.15. BIOMERIEUX S.A.
7.16. BIOPORTO A/S
7.17. BIO-RAD LABORATORIES
7.18. CISBIO BIOASSAYS
7.19. COVANCE INC.
7.20. CRITICAL DIAGNOSTICS INC.
7.21. DIAGENIC ASA
7.22. ENZO LIFE SCIENCES, INC.
7.23. EUROIMMUN AG
7.24. EVOTEC A.G.
7.25. EXACT SCIENCE CORPORATION
7.26. F. HOFFMANN-LA ROCHE LTD.
7.27. GENENEWS LTD.
7.28. ILLUMINA, INC.
7.29. INOVA DIAGNOSTIC INC.
7.30. LUMINEX CORPORATION
7.31. MERCK & CO. INC.
7.32. METABOLON INC.
7.33. MYRIAD GENETICS INC.
7.34. NANOSTRING TECHNOLOGIES INC.
7.35. NOVARTIS AG
7.36. PACIFIC BIOMARKERS INC.
7.37. PLATO BIO PHARMA INC.
7.38. PLIANT THERAPEUTICS, INC.
7.39. QIAGEN N.V.
7.40. QUEST DIAGNOSTICS INC.
7.41. R & D SYSTEMS
7.42. RANDOX LABORATORIES LTD.
7.43. RESPONSE BIOMEDICAL CORPORATION
7.44. SIEMENS AG
7.45. SIGNOSIS INC.
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
CHAPTER 2. MARKET OVERVIEW AND INSIGHTS
2.1. MARKET DEFINITION
2.2. PARENT MARKET ANALYSIS: GLOBAL BIOMARKER MARKET
2.3. ANALYST INSIGHT & CURRENT MARKET TRENDS
2.3.1. KEY FINDINGS
2.3.2. RECOMMENDATION
2.3.3. CONCLUSION
2.4. RULES & REGULATIONS
2.4.1.1. UNITED STATES
2.4.1.2. EUROPEAN UNION
2.4.1.3. CHINA
2.4.1.4. JAPAN
2.4.1.5. INDIA
CHAPTER 3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. RISING PREVALENCE OF CHRONIC DISEASES
3.1.2. HIGH NUMBER OF RESEARCH INSTITUTES FOCUSED ON DIAGNOSTIC BIOMARKERS
3.1.3. SIGNIFICANT GROWTH IN THE SECTOR OF MOLECULAR BIOLOGY
3.1.4. ADVANCEMENTS IN VARIOUS LABORATORY TECHNIQUES
3.1.5. ADVANCES IN BIOMEDICAL TECHNOLOGIES SUCH AS MICRO-RNA (MIRNA)
3.2. RESTRAINTS
3.2.1. LACK OF REGULATORY & REIMBURSEMENT SYSTEMS
3.2.2. HIGH CAPITAL INVESTMENTS IS REQUIRED AND PROFIT RATIO IS LOW
3.2.3. LIMITED AVAILABILITY OF THE RESOURCES AND LIMITED STUDIES RELATED TO THE DIAGNOSTIC BIOMARKERS
3.3. OPPORTUNITIES
3.3.1. INCREASING DEMAND OF PERSONALIZED MEDICINE
3.3.2. ACTIVE FUNDING OPPORTUNITIES FOR RESEARCH INSTITUTES
CHAPTER 4. MARKET SEGMENTATION
4.1. GLOBAL DIAGNOSTIC BIOMARKER MARKET, BY APPLICATION
4.1.1. ONCOLOGY
4.1.2. CARDIOLOGY
4.1.3. NEUROLOGY
4.1.4. NEPHROLOGY
4.1.5. OTHER (CYSTIC FIBROSIS, ASPERGILLOSIS, AND TYPE 2 DIABETES MELLITUS (DM))
4.2. GLOBAL DIAGNOSTIC BIOMARKER MARKET, BY DIAGNOSTIC TECHNIQUE
4.2.1. ELISA
4.2.2. COLORIMETRIC ASSAY
4.2.3. LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY
4.2.4. PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY
4.2.5. OTHER
4.3. GLOBAL DIAGNOSTIC BIOMARKER BY END USERS
4.3.1. HOSPITALS & DIAGNOSTIC LABS
4.3.2. RESEARCH CENTRES
CHAPTER 5. COMPETITIVE LANDSCAPE
5.1. KEY COMPANY ANALYSIS
5.2. KEY STRATEGY ANALYSIS
CHAPTER 6. REGIONAL ANALYSIS
6.1. NORTH AMERICAN
6.1.1. UNITED STATES
6.1.2. CANADA
6.2. EUROPE
6.2.1. U.K
6.2.2. GERMANY
6.2.3. ITALY
6.2.4. SPAIN
6.2.5. FRANCE
6.2.6. ROE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.3.4. ROAPAC
6.4. REST OF THE WORLD
CHAPTER 7. COMPANY PROFILES
7.1. ABASTAR MDX INC.
7.2. ABBOTT LABORATORIES INC.
7.3. ACUMEN PHARMACEUTICALS INC.
7.4. ADLYFE INC.
7.5. AGENDIA BV
7.6. ASTELLAS PHARMA INC.
7.7. ASTUTE MEDICAL, INC.
7.8. AVACTA GROUP PLC
7.9. BANYAN BIOMARKERS
7.10. BAYER AG
7.11. BECKMAN COULTER INC.
7.12. BECTON, DICKSON & CO.
7.13. BG MEDICINE INC.
7.14. BIOMARKER TECHNOLOGIES, INC.
7.15. BIOMERIEUX S.A.
7.16. BIOPORTO A/S
7.17. BIO-RAD LABORATORIES
7.18. CISBIO BIOASSAYS
7.19. COVANCE INC.
7.20. CRITICAL DIAGNOSTICS INC.
7.21. DIAGENIC ASA
7.22. ENZO LIFE SCIENCES, INC.
7.23. EUROIMMUN AG
7.24. EVOTEC A.G.
7.25. EXACT SCIENCE CORPORATION
7.26. F. HOFFMANN-LA ROCHE LTD.
7.27. GENENEWS LTD.
7.28. ILLUMINA, INC.
7.29. INOVA DIAGNOSTIC INC.
7.30. LUMINEX CORPORATION
7.31. MERCK & CO. INC.
7.32. METABOLON INC.
7.33. MYRIAD GENETICS INC.
7.34. NANOSTRING TECHNOLOGIES INC.
7.35. NOVARTIS AG
7.36. PACIFIC BIOMARKERS INC.
7.37. PLATO BIO PHARMA INC.
7.38. PLIANT THERAPEUTICS, INC.
7.39. QIAGEN N.V.
7.40. QUEST DIAGNOSTICS INC.
7.41. R & D SYSTEMS
7.42. RANDOX LABORATORIES LTD.
7.43. RESPONSE BIOMEDICAL CORPORATION
7.44. SIEMENS AG
7.45. SIGNOSIS INC.
LIST OF TABLES
TABLE 1 GLOBAL DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
TABLE 2 GLOBAL ONCOLOGY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 3 GLOBAL CARDIOLOGY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 4 GLOBAL NEUROLOGY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 5 GLOBAL NEPHROLOGY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 6 GLOBAL OTHER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 7 GLOBAL DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TECHNIQUE, 2017-2023 ($ MILLION)
TABLE 8 GLOBAL ELISA MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 9 GLOBAL COLORIMETRIC ASSAY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 10 GLOBAL LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 11 GLOBAL PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 12 GLOBAL DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 13 GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 14 GLOBAL DIAGNOSTIC LABS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 15 GLOBAL RESEARCH CENTRES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 16 NORTH AMERICAN DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 17 NORTH AMERICAN DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
TABLE 18 NORTH AMERICAN DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TECHNIQUE, 2017-2023 ($ MILLION)
TABLE 19 NORTH AMERICAN DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 20 EUROPEAN DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 21 EUROPEAN DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
TABLE 22 EUROPEAN DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TECHNIQUE, 2017-2023 ($ MILLION)
TABLE 23 EUROPEAN DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 24 APAC DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 25 APAC DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
TABLE 26 APAC DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TECHNIQUE, 2017-2023 ($ MILLION)
TABLE 27 APAC DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 28 ROW DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
TABLE 29 ROW DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TECHNIQUE, 2017-2023 ($ MILLION)
TABLE 30 ROW DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 1 GLOBAL DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
TABLE 2 GLOBAL ONCOLOGY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 3 GLOBAL CARDIOLOGY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 4 GLOBAL NEUROLOGY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 5 GLOBAL NEPHROLOGY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 6 GLOBAL OTHER MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 7 GLOBAL DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TECHNIQUE, 2017-2023 ($ MILLION)
TABLE 8 GLOBAL ELISA MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 9 GLOBAL COLORIMETRIC ASSAY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 10 GLOBAL LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 11 GLOBAL PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 12 GLOBAL DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 13 GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 14 GLOBAL DIAGNOSTIC LABS MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 15 GLOBAL RESEARCH CENTRES MARKET RESEARCH AND ANALYSIS, 2017-2023 ($ MILLION)
TABLE 16 NORTH AMERICAN DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 17 NORTH AMERICAN DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
TABLE 18 NORTH AMERICAN DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TECHNIQUE, 2017-2023 ($ MILLION)
TABLE 19 NORTH AMERICAN DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 20 EUROPEAN DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 21 EUROPEAN DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
TABLE 22 EUROPEAN DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TECHNIQUE, 2017-2023 ($ MILLION)
TABLE 23 EUROPEAN DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 24 APAC DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2017-2023 ($ MILLION)
TABLE 25 APAC DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
TABLE 26 APAC DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TECHNIQUE, 2017-2023 ($ MILLION)
TABLE 27 APAC DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
TABLE 28 ROW DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2017-2023 ($ MILLION)
TABLE 29 ROW DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY DIAGNOSTIC TECHNIQUE, 2017-2023 ($ MILLION)
TABLE 30 ROW DIAGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS BY END USERS, 2017-2023 ($ MILLION)
LIST OF FIGURES
FIGURE 1 GLOBAL DIAGNOSTIC BIOMARKER MARKET SHARE BY APPLICATION, 2017 VS 2023 (%)
FIGURE 2 GLOBAL DIAGNOSTIC BIOMARKER MARKET SHARE BY DIAGNOSTIC TECHNIQUE, 2017 VS 2023 (%)
FIGURE 3 GLOBAL DIAGNOSTIC BIOMARKER MARKET SHARE BY END USERS, 2017 VS 2023 (%)
FIGURE 4 US DIAGNOSTIC BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 5 CANADA DIAGNOSTIC BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 6 UK DIAGNOSTIC BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 7 FRANCE DIAGNOSTIC BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 8 GERMANY DIAGNOSTIC BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 9 ITALY DIAGNOSTIC BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 10 SPAIN DIAGNOSTIC BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 11 ROE DIAGNOSTIC BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 12 INDIA DIAGNOSTIC BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 13 CHINA DIAGNOSTIC BIOMARKER MARKETSIZE, 2017-2023 ($ MILLION)
FIGURE 14 TAIWAN DIAGNOSTIC BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 15 JAPAN DIAGNOSTIC BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 16 ROAPAC DIAGNOSTIC BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 17 REST OF THE WORLD DIAGNOSTIC BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
COMPANIES MENTIONED
1. ABASTAR MDX INC.
2. ABBOTT LABORATORIES INC.
3. ACUMEN PHARMACEUTICALS INC.
4. ADLYFE INC.
5. AGENDIA BV
6. ASTELLAS PHARMA INC.
7. ASTUTE MEDICAL, INC.
8. AVACTA GROUP PLC
9. BANYAN BIOMARKERS
10. BAYER AG
11. BECKMAN COULTER INC.
12. BECTON, DICKSON & CO.
13. BG MEDICINE INC.
14. BIOMARKER TECHNOLOGIES, INC.
15. BIOMERIEUX S.A.
16. BIOPORTO A/S
17. BIO-RAD LABORATORIES
18. CISBIO BIOASSAYS
19. COVANCE INC.
20. CRITICAL DIAGNOSTICS INC.
21. DIAGENIC ASA
22. ENZO LIFE SCIENCES, INC.
23. EUROIMMUN AG
24. EVOTEC A.G.
25. EXACT SCIENCE CORPORATION
26. F. HOFFMANN-LA ROCHE LTD.
27. GENENEWS LTD.
28. ILLUMINA, INC.
29. INOVA DIAGNOSTIC INC.
30. LUMINEX CORPORATION
31. MERCK & CO. INC.
32. METABOLON INC.
33. MYRIAD GENETICS INC.
34. NANOSTRING TECHNOLOGIES INC.
35. NOVARTIS AG
36. PACIFIC BIOMARKERS INC.
37. PLATO BIO PHARMA INC.
38. PLIANT THERAPEUTICS, INC.
39. QIAGEN N.V.
40. QUEST DIAGNOSTICS INC.
41. R & D SYSTEMS
42. RANDOX LABORATORIES LTD.
43. RESPONSE BIOMEDICAL CORPORATION
44. SIEMENS AG
45. SIGNOSIS INC.
FIGURE 1 GLOBAL DIAGNOSTIC BIOMARKER MARKET SHARE BY APPLICATION, 2017 VS 2023 (%)
FIGURE 2 GLOBAL DIAGNOSTIC BIOMARKER MARKET SHARE BY DIAGNOSTIC TECHNIQUE, 2017 VS 2023 (%)
FIGURE 3 GLOBAL DIAGNOSTIC BIOMARKER MARKET SHARE BY END USERS, 2017 VS 2023 (%)
FIGURE 4 US DIAGNOSTIC BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 5 CANADA DIAGNOSTIC BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 6 UK DIAGNOSTIC BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 7 FRANCE DIAGNOSTIC BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 8 GERMANY DIAGNOSTIC BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 9 ITALY DIAGNOSTIC BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 10 SPAIN DIAGNOSTIC BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 11 ROE DIAGNOSTIC BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 12 INDIA DIAGNOSTIC BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 13 CHINA DIAGNOSTIC BIOMARKER MARKETSIZE, 2017-2023 ($ MILLION)
FIGURE 14 TAIWAN DIAGNOSTIC BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 15 JAPAN DIAGNOSTIC BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 16 ROAPAC DIAGNOSTIC BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
FIGURE 17 REST OF THE WORLD DIAGNOSTIC BIOMARKER MARKET SIZE, 2017-2023 ($ MILLION)
COMPANIES MENTIONED
1. ABASTAR MDX INC.
2. ABBOTT LABORATORIES INC.
3. ACUMEN PHARMACEUTICALS INC.
4. ADLYFE INC.
5. AGENDIA BV
6. ASTELLAS PHARMA INC.
7. ASTUTE MEDICAL, INC.
8. AVACTA GROUP PLC
9. BANYAN BIOMARKERS
10. BAYER AG
11. BECKMAN COULTER INC.
12. BECTON, DICKSON & CO.
13. BG MEDICINE INC.
14. BIOMARKER TECHNOLOGIES, INC.
15. BIOMERIEUX S.A.
16. BIOPORTO A/S
17. BIO-RAD LABORATORIES
18. CISBIO BIOASSAYS
19. COVANCE INC.
20. CRITICAL DIAGNOSTICS INC.
21. DIAGENIC ASA
22. ENZO LIFE SCIENCES, INC.
23. EUROIMMUN AG
24. EVOTEC A.G.
25. EXACT SCIENCE CORPORATION
26. F. HOFFMANN-LA ROCHE LTD.
27. GENENEWS LTD.
28. ILLUMINA, INC.
29. INOVA DIAGNOSTIC INC.
30. LUMINEX CORPORATION
31. MERCK & CO. INC.
32. METABOLON INC.
33. MYRIAD GENETICS INC.
34. NANOSTRING TECHNOLOGIES INC.
35. NOVARTIS AG
36. PACIFIC BIOMARKERS INC.
37. PLATO BIO PHARMA INC.
38. PLIANT THERAPEUTICS, INC.
39. QIAGEN N.V.
40. QUEST DIAGNOSTICS INC.
41. R & D SYSTEMS
42. RANDOX LABORATORIES LTD.
43. RESPONSE BIOMEDICAL CORPORATION
44. SIEMENS AG
45. SIGNOSIS INC.
